key: cord-0864114-iopenj3b
authors: Mortaz, Esmaeil; Jamaati, Hamidreza; Roofchayee, Neda Dalil; Sheikhzade, Hakime; Mirenayat, Maryam; Sadeghi, Mohsen; Lookzadeh, Somayeh; Dezfuli, Neda K.; Folkerts, Gert; Mumby, Sharon; Garssen, Johan; Adcock, Ian M.
title: Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery
date: 2022-02-16
journal: Heliyon
DOI: 10.1016/j.heliyon.2022.e08957
sha: 80501a7cd4e435b1dceac8c57de4deed8644643a
doc_id: 864114
cord_uid: iopenj3b

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Circulating soluble angiotensin-converting enzyme (sACE2)2, the main receptor for SARS-CoV-2, together with components of the renin-angiotensin system promote infection and disease severity. OBJECTIVE: This pilot study followed the time-course of sACE2 levels in relation to systemic cytokines in severe and moderate COVID-19 patients treated with remdesivir/dexamethasone in combination. METHODS: Peripheral blood was obtained upon admission from 30 patients (12 with moderate disease and 18 with severe disease) and 14 patients with PCR-confirmed mild COVID-19. Severe and moderate patients were treated with remdesivir (200mg/first day and 100mg/day for the remaining days) and dexamethasone (100mg/day). 6 healthy control subjects (HC) were also enrolled. Serum interleukin (IL)-6 and IL-8 and sACE2 levels were measured by ELISA at baseline and during treatment in severe and moderate patients and at baseline in mild and HCs. RESULTS: Baseline sACE2 levels were lower in severe (p=0.0005) and moderate (p=0.0022) patients than in patients with mild COVID-19 and in HC (p=0.0023 and p=0.0012 respectively). Treatment significantly increased sACE2 levels in patients with moderate disease (p=0.0156) but only 50% of patients with severe disease showed enhanced levels compared to baseline. Systemic IL-6 and IL-8 levels were higher in all patient groups compared with HC and were not significantly affected over time or by remdesivir/dexamethasone treatment for 5 days. Conclusion: Serum sACE2 levels increase in severe COVID-19 patients as they recover over time whilst circulating cytokines are unaffected. Future studies should link these results to clinical outcomes.

Severe acute respiratory syndrome virus 2 (SARS-CoV-2) causes a respiratory disease that led to the fatal Coronavirus disease 2019 (COVID- 19) pandemic (1) . COVID-19 is heterogeneous and manifests clinically with fever, cough, muscle pain, fatigue, loss of taste and smell, diarrhoea and pneumonia and may result in death in susceptible subjects (2) (3) (4) . Patients with poor prognostic features upon hospital admission frequently encounter complications with significant mortality associated with acute respiratory distress syndrome (ARDS), multi-organ failure and blood clots (5) .

The renin-angiotensin system (RAS) maintains blood pressure and electrolyte balance in the body and has been implicated in the pathogenesis of ARDS also (6) . RAS operates via two axes: the classic angiotensin converting enzyme (ACE)/Angiotensin (Ang) II/Ang II type 1 (AT1) receptor axis and the non-classical ACE2/Ang 1-7/Mas receptor (MasR) axis. These two pathways have opposing functions: whilst the former is associated with impairment of respiratory conditions the latter plays a protective role in ARDS (7) . Thus, determining the role of RAS in the pathogenesis of COVID-19 in controlling, monitoring and management of COVID-19 is essential.

ACE2 is a carboxypeptidase and type I transmembrane protein with an extracellular Nterminal domain containing the active site (8) and is recognised as a receptor for SARS-CoV-2 infection (9) . ACE2 is secreted into the systemic circulation as an enzymatically active ectodomain also (8) . After binding to ACE2 and entry of the SARS-CoV-2 to the target cells, shedding of host ACE2 receptors occurs that may disrupt RAS tissue homeostasis leading to important implications for COVID-19 severity (10) (11) (12) . Interaction of RAS-associated proteins with circulating soluble ACE2 (sACE2) is essential for SARS-CoV-2-mediated entry (13) . Furthermore, injection of recombinant ACE2 has a potential therapeutic role in treating patients infected with SARS-CoV-2 (12) (13) (14) .

We hypothesised that increased sACE2 levels may protect against severe COVID-19 by blocking viral entry to target cells (15) (16) (17) . Thus, we investigated the levels of sACE2 in mild, moderate and severe COVID-19 patients and assessed whether an anti-viral treatment together with dexamethasone affected sACE2 levels.

J o u r n a l P r e -p r o o f Thirty confirmed COVID-19 patients including 18 patients with severe disease, 12 with moderate disease and 14 subjects with mild disease who did not require hospitalization were enrolled into the study upon admission to the Masih Daneshvari Hospital of Shahid Beheshti Medical University (Tehran-Iran) between Jan. 10 th -Feb. 5 th , 2021. Six healthy control subjects (HC) were enrolled as controls. All patients were diagnosed according to World Health Organization (WHO) interim (18, 19) . All COVID-19 patients were confirmed as polymerase chain reaction (PCR) positive using specific primers for SARS-CoV-2 in their nasopharyngeal samples.

Severe COVID-19 disease was confirmed by the presence of at least one of the following: respiratory rate >30/min; blood oxygen saturation ≤90% on room air; ratio of partial pressure of oxygen in arterial blood to the inspired oxygen fraction (PaO2FiO2) <300 and lung infiltrates present on >50% of the lung fields. In contrast, patients with moderate disease were characterized with respiratory rate ≥24 and SpO2 ≤93% on room air and mild disease was characterized by upper respiratory tract symptoms without shortness of breath or hypoxia (20 

The clinical records of patients were interpreted by the research team of the Department of Critical Care Medicine, Masih Daneshvari Hospital of Shahid Beheshti University.

Clinical, laboratory, and radiological properties and treatments and outcomes data were collated from electronic medical records. The information recorded included demographic data, medical history, underlying comorbidities, symptoms, signs, laboratory findings; chest computed tomographic (CT) scans, and treatment measures.

The antiviral treatment in this study for the moderate and severe patients was remdesivir (200mg/ first day and 100mg/day for the 4 days) with dexamethasone (100mg/day) as previously described (21) . Besides in all severe patients were treated with methylprednisolone (125 mg-500 mg) for three days and for rest with J o u r n a l P r e -p r o o f dexamethasone (8-16 mg for 5 days) and the moderate patient only got dexamethasone as the same as severe patients. In addition, all patients with severe disease received a single dose of Actemra (anti-IL-6, 8 mg/kg) upon admission to hospital as recommended (22) .

Blood (3ml in tubes without anticoagulants) was obtained at baseline and 5 days after the male/female ratio in J o u r n a l P r e -p r o o f

Basic demographic and clinical characteristics of the participants are shown in Table 1 .

The mean age of the COVID-19 patients was not significantly different from that of the healthy controls (57.1 ± 2.6 versus 46.5 ± 6.2 years, p=0.1043) but gender was different due to all the control subjects being male. Table 1 also shows the respiratory rate (RR), CT values and SpO2 and APACHEII of subjects at baseline.

Serum ESR (p=0.0013), CRP (p=0.0067), LDH (p=0.0004) and CPK (p=0.0077) levels were higher in severe COVID-19 patients at baseline than in mild patients whilst baseline levels of all but CPK (p=0.1193) were also higher in moderate patients compared with mild patients ( Table 2) . These were not measure in healthy subjects.

Over time, the serum levels of ESR (p=0.0273) and CRP (p=0.0049) were significantly reduced in severe patients. Similarly, CRP (p=0.002) and ESR (p=0.0195) levels were significantly reduced in patients with moderate disease ( Table 2) . This coincided with the introduction of remdesivir and dexamethasone therapy for 5-7 days.. Overall, the serum levels of ESR and CRP in severe patients after 5-7 days treatment with remdesivir and dexamethasone were similar to those seen in mild patients whilst the level of LDH (p=0.0031) and CPK (p=0.0065) remained significantly different from those in mild subjects ( Table 2 ). In comparison, only the serum levels of LDH in moderate COVID-19 patients after 5-7 days were significantly different (p<0.0001) from the levels seen in subjects with mild disease ( Table 2) . There was no significant difference in LDH, CRP, ESR and CPK levels between severe and moderate patients ( Table 2) .

Baseline sACE2 levels in severe patients were significantly lower than observed in patients with mild COVID-19 (p=0.0005) or HC (p=0.0022) (Fig. 1A , Tables 3 & 4) .

Similarly, baseline sACE2 levels in moderate COVID-19 patients were also significantly lower than observed in patients with mild disease (p=0.0023) or HC (p=0.0012) ( and there was no difference observed in these levels in association with severity. In addition, there was no significant change in the levels of these cytokines before and after treatment for any severity group ( Fig. 2A- 

Serum IL-8 levels were also significantly elevated in COVID-19 patients compared to HC at baseline (Fig. 3A, Tables 3 & 4) . There was no significant change in the levels of IL-8 before and after treatment for any severity group ( Fig. 3B-C, Tables 3 & 4 ).

The serum sACE2 levels were analysed according to sex in moderate and severe J o u r n a l P r e -p r o o f required in a larger multi-centre cohort to determine the precise link between ARDS and sACE2 levels.

An age-and sex-relationship between ACE2 in humans exists. sACE2 levels are low in both sexes up to the age of 12 whereupon it increases to a greater extent in males such that males older than 15 have higher sACE2 levels than women (32) . In our study, we found no relationship between sACE2 and age but did report a significant difference between sexes at baseline in sACE2 levels. This difference was lost over time/with treatment.

Higher levels of sACE2 are associated with a greater risk for severe COVID-19 (33) which may explain the greater susceptibility to infection by SARS-CoV-2. Smoking and individuals with Type 2 diabetes and/or obesity also have higher serum sACE2 levels (34) . However, plasma concentrations of sACE2 are much lower in diabetics with chronic disease than in healthy controls and are further reduced by the use of hypoglycemia drugs. This may provide a rationale for why diabetics with lower plasma levels of sACE2 may be more susceptible to severe COVID-19 (35) .

Serum levels of circulating sACE2 should be considered as a potential interface between chronic inflammation, cardiovascular disease and COVID-19 susceptibility (36) . Elderly patients with aortic stenosis have markedly elevated serum ACE2 levels together with altered left and right ventricular functions, which may pose higher risks during COVID-19 (36) . In addition, high plasma sACE2 levels may be a predictor of COVID-19 severity and outcomes as well as a risk factor for hypertension, pre-existing heart disease and pre-existing kidney disease (37) . In contrast, in lung diseases circulating sACE2 levels were significantly reduced in COPD and pulmonary fibrosis (PF) compared to healthy control (38) . sACE2 levels may merely reflect the inflammatory state which is indicated by serum CRP levels. CRP levels at baseline were significantly higher in the severe and moderate COVID-19 patients compared to those with mild disease and significantly lowered with time/treatment. It is possible, therefore, that as sACE2 levels track inversely with CRP levels that there is a causal effect. This requires further investigation.

Thus, age and co-morbidities may be important confounders, but it is unlikely that the age of the patients is a confounding factor in this study since all of participants are J o u r n a l P r e -p r o o f adults of a similar age. Furthermore, there was no link between sACE2 levels and any underlying diabetes, smoking and hypertension in severe and moderate COVID-19 patients in this study (data not shown).

Despite the changes observed in sACE2 levels we did not find any significant differences in serum IL-6 or IL-8 levels over the duration of the study. Many studies (39, 40) report that mild patients have lower IL-6 and IL-8 levels as compared to moderate and severe patients and severe patients have higher levels of IL-6 and IL-8 as compared to moderate patients. Although we did not find a significant difference in cytokine levels between patients with mild, moderate and severe forms of the disease, there is trend towards an increase in these levels between groups. This may reflect the low number in our study but may also reflect other factors such as the precise timing of sample collection after infection and/or hospitalization. In addition, the timing and/or dose of the dexamethasone treatment in these patients or potential ethnic differences between patients recruited here and in other studies may affect the results.

Although there are several strengths to our study we recognize that there are some limitations. These include the low number of participants, having only males in the healthy control group is a limitation of the study as is the collection of samples from only subsets of recruited patients rather than all subjects. In addition, we do not have untreated, severe COVID-19 subjects to act as controls as this would not be allowed by our Ethics Committee. Although we measured IL-6 and IL-8 levels, the cytokine storm involves many more cytokines (40) . A more complete picture of the changes in the cytokine storm following time/treatment using multiplex analysis should be undertaken in future studies.

In J o u r n a l P r e -p r o o f Comparisons of data between the groups were performed using the Mann-Whitney U test. *Comparisons of treatment effects within groups were performed using the paired Wilcoxon test.

J o u r n a l P r e -p r o o f 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet Respiratory Medicine

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

COVID-19 pathophysiology: A review

The immune response and immunopathology of COVID-19

Differentiating COVID-19 pneumonia from acute respiratory distress syndrome and high altitude pulmonary edema: therapeutic implications

The renin-angiotensin system in acute respiratory distress syndrome

Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cellular and molecular life sciences

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Receptor Recognition by the Novel Coronavirus from Wuhan:An analysis based on decade-long structural studies of SARS 3 2020

Guan Bet al. Un papel crucial de la enzima convertidora de angiotensina 2 (ACE2) en la lesión pulmonar inducida por coronavirus del SARS

A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captoprilinsensitive carboxypeptidase

ACE2, much more than just a receptor for SARS-COV-2. Frontiers in cellular and infection microbiology

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the reninangiotensin system

Inflammation triggered by sars-cov-2 and ace2 augment drives multiple organ failure of severe covid-19: Molecular mechanisms and implications

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic

Mild or moderate COVID-19

Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses

A strategic approach to COVID-19 vaccine R&D

Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)

Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63

Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19

ACE2 as Drug Target of COVID-19 Virus Treatment

Human recombinant soluble ACE2 in severe COVID-19. The Lancet Respiratory Medicine

Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome

Age and sex differences in soluble ACE2 may give insights for COVID-19

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Serum levels of ACE2 are higher in patients with obesity and diabetes

Low plasma angiotensinconverting enzyme 2 level in diabetics increases the risk of severe COVID-19 infection

Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity

Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients

Dysbalance of ACE2 levels-a possible cause for severe COVID-19 outcome in COPD

An inflammatory cytokine signature predicts COVID-19 severity and survival

Distinct cytokine profiles associated with COVID-19 severity and mortality

We thank all the patients and their families who participated in this research. We thank all members of our laboratories for critical input and suggestions.

Esmaeil Mortaz, conceived and designed the experiments, performed the experiments, analyzed and interpreted the data and wrote the paper. Neda Dalil Roofchayee analyzed and interpreted the data, contributed reagents, materials, analysis tools or data and wrote the paper. Hamidreza Jamaati,, Hakime Sheikhzade, Maryam Mirenayat, Mohsen Sadeghi, Somayeh Lookzadeh provide the patients samples, interpreted the data and contributed reagents, materials, analysis tools or data. Neda K Dezfuli contributed analysis tools or data. Gert Folkerts, Sharon Mumby, Johan Garssen and Ian M. Adcock , conceived and designed the experiments, analyzed, interpreted the data and revised the paper.J o u r n a l P r e -p r o o f

The authors declare that there is no conflict of interest to this article.